ECOG-ACRIN Cancer Research Group

01/21/2026

EA7222, led by Dr. Seth Pollack of , is a randomized phase 3 trial of doxorubicin alone or in combination with pembrolizumab for patients with advanced soft tissue sarcoma and related poorly differentiated sarcomas that are unresectable. https://bit.ly/EA7222

01/21/2026

In the Study, researchers are testing if genetically-matched drug combinations will be more effective than single drugs for certain patients with . Learn more: http://bit.ly/ComboMATCH

01/21/2026

is up—but sustained research funding and equitable access to screening & treatment are key to continued progress. Learn more via ABC News: https://bit.ly/3NvFTv0

The five-year relative survival for all cancers combined has reached a milestone, according to the American Cancer Society.

01/20/2026

Do you have an aggressive B-cell lymphoma that has either come back or persisted after initial therapy? If so, you may be eligible to participate in clinical trial EA4231. More info here: https://bit.ly/EA4231

01/20/2026

Urothelial cancer is the most common type of bladder cancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. https://bit.ly/ea8192-trial

01/19/2026

ComboMATCH/EAY191-E5 tests how well with or without can treat patients with advanced solid tumors. For more information: https://bit.ly/combomatch-e5

01/19/2026

In clinical trial EA7211/STRASS 2, investigators are testing neoadjuvant chemotherapy followed by surgery vs. surgery alone for patients with high-risk retroperitoneal . More info: https://bit.ly/EA7211

01/19/2026

Why does breast cancer come back after treatment? The EA1241 , led by Dr. Joseph Sparano, aims to find out by evaluating tissue samples from patients who previously enrolled in TAILORx & RxPONDER. More: https://bit.ly/EA1241

01/16/2026

: ICYMI, researchers shared new findings from the PATINA metastatic trial at . Palbociclib + anti-HER2 & endocrine therapy may help delay or prevent CNS involvement in HR+/HER2+ . Learn more: https://bit.ly/3YD9eGh cc:

01/16/2026

Clinical trial MM1OA-EA02, led by Dr. Jessica Altman of the Lurie Cancer Center, aims to improve results for older adults with acute myeloid leukemia (AML). Learn more: https://bit.ly/mm1oa-ea02-study

01/16/2026

Clinical trial EAF223/GABLE, led by Dr. Daniel Barboriak, aims to help newly diagnosed patients with by testing a new treatment approach. Learn more: https://bit.ly/gable-trial

01/16/2026

ECOG-ACRIN is hosting a webinar on EA1241, a companion study for patients previously enrolled in TAILORx or RxPONDER. Investigators & professionals are invited to register below.

📅Feb 4 | 4 PM ET
🎙 Joseph Sparano, MD, Kevin Kalinsky, MD, MS, & Rima Patel, MD
🔗https://bit.ly/EA1241webinar